S-3794-119
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
Sponsored by Jim Banks (R-IN)
What it does
This bill would narrow the definition of when a compounded drug is considered "essentially a copy" of a commercially available drug, making it easier for pharmacists and physicians to compound drugs with any active ingredient found in a commercial product. It would raise the monthly limit for compounding such copies from 4 to 20 prescriptions per month. It would also require annual reporting from physicians, non-hospital pharmacies, and facilities that compound certain drugs for out-of-state patients more than 20 times per month, and would subject large-scale outsourcing facilities to regular inspections and reporting requirements.
Who benefits
Patients who need customized drug formulations — such as those with allergies to inactive ingredients, difficulty swallowing standard doses, or needs not met by commercial products. Compounding pharmacies and physicians who would gain more flexibility under the higher monthly limit. Patients in areas with drug shortages who rely on compounded alternatives. Small compounding pharmacies that may benefit from a clearer, narrower definition of "essentially a copy." Patients requiring out-of-state compounded drugs who may benefit from increased transparency and safety oversight.
Who is hurt
Large-scale outsourcing facilities that would face new inspection and reporting burdens and associated compliance costs. Physicians and non-hospital pharmacies compounding for out-of-state patients above the 20-per-month threshold, who would face new annual reporting requirements. Brand-name pharmaceutical manufacturers, who may face increased competition from compounded versions of their products under the expanded monthly limit. Patients who rely on large-volume outsourcing facilities, which could face higher costs or reduced output due to compliance requirements. Hospital-based pharmacies are exempt from reporting, potentially creating an uneven regulatory landscape for non-hospital competitors.
Supporters argue
Supporters argue that the FDA's current four-prescription monthly limit is arbitrarily restrictive and prevents patients with legitimate medical needs — such as allergies to dyes or preservatives in commercial drugs — from accessing necessary medications. They contend that the bill's narrower definition of "essentially a copy" better reflects clinical reality, since a drug with the same active ingredient but a different formulation can produce meaningfully different outcomes for individual patients. They also argue that the new inspection and reporting requirements for large outsourcing facilities directly address the safety failures exposed by the 2012 New England Compounding Center meningitis outbreak, which killed 64 people.
Opponents argue
Opponents argue that raising the monthly compounding limit from 4 to 20 prescriptions significantly expands access to unapproved drug copies, undermining the FDA approval process that ensures safety and efficacy for the broader patient population. They contend that the narrower "essentially a copy" definition creates a loophole that could allow compounders to produce large quantities of commercial drug substitutes with minimal clinical justification, potentially exposing patients to drugs of unverified quality. They further argue that exempting hospital-based pharmacies from reporting requirements creates an inconsistent oversight framework that may allow safety risks to go undetected in high-volume hospital compounding operations.
Constitutional context
Congress regulates drug compounding under its Commerce Clause authority (Art. I, §8, cl. 3), as compounded drugs frequently cross state lines. The FDA's existing compounding regulations have been upheld under this authority. Post-Loper Bright (2024), any FDA regulatory interpretations implementing this bill's provisions — such as defining "significant difference" or setting inspection standards — would face independent judicial review rather than automatic deference, potentially increasing litigation risk around agency implementation choices.
Checks and balances
Congress sets the statutory limits and reporting requirements; the FDA retains authority to implement and enforce through inspections and rulemaking, subject to heightened judicial scrutiny under Loper Bright (2024).
Historical precedent
The Drug Quality and Security Act of 2013 was enacted in direct response to the 2012 New England Compounding Center meningitis outbreak and established the current federal framework for compounding oversight, including the outsourcing facility category this bill would subject to new inspections.